EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • July 16th, 2019 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • Washington
THIS EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into as of the 20th day of May, 2019, by and between SEATTLE GENETICS, INC., a Delaware corporation (“Company”) and Robin Taylor (“Executive”).
TO DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • July 16th, 2019 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances)
Effective as of the date of the last signature below, AbbVie Inc. (the successor-in-interest to Abbott Laboratories), a Delaware corporation having a principal place of business at 1 N Waukegan Road, North Chicago, IL 60064 (“AbbVie”), and Seattle Genetics, Inc., a Delaware corporation having a principal place of business at 21823 – 30th Drive Southeast in Bothell, Washington 98021 (“Seattle Genetics”) (individually the “Party” or collectively the “Parties”) agree to the following terms and conditions as set forth below (this “Twelfth Amendment”). Capitalized terms used but not defined herein shall have the meaning ascribed to them in the Agreement (as defined below).
JOINT COMMERCIALIZATION AGREEMENTJoint Commercialization Agreement • July 16th, 2019 • Seattle Genetics Inc /Wa • Biological products, (no disgnostic substances) • California
[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED.
